SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors speculate on a major buyout and a potential short squeeze, fueled by record short interest and anticipation for upcoming trial data. The community is heavily focused on the stock's upward momentum and the intense pressure building on short sellers to cover their positions before the weekend.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending due to intense volatility and extreme community polarization regarding Michael Saylor's leveraged Bitcoin-accumulation strategy, with the stock experiencing sharp downward pressure that has left many investors debating whether this represents a generational buying opportunity or a looming insolvency event. Traders are intensely focused on market-maker activity, options expiration, and the company's reliance on share dilution to maintain its Bitcoin holdings as broader market sentiment toward the crypto sector remains highly uncertain.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors monitor an upcoming court hearing over commercial rights alongside high anticipation for an August PDUFA decision for Deramiocel. The community is actively debating the impact of these legal proceedings on the company's path to market and the potential for a favorable FDA label expansion given the positive phase 3 and long-term extension data.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is facing intense volatility and selling pressure as investors grapple with debt concerns, leadership criticism, and the company's recent move into AI infrastructure partnerships. The community remains deeply divided, with some traders viewing the current price as a tactical buying opportunity while others express significant skepticism regarding management's strategic direction and the impact of the ongoing steel price environment.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is drawing significant investor interest as the market closely monitors the tension between its surging AI data center revenue and ongoing weakness in the automotive and industrial sectors. Community sentiment is deeply polarized, with active debates centered on whether the current stock performance represents a sustainable breakout driven by infrastructure demand or an overextended valuation vulnerable to structural dilution and sector-wide headwinds.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors digest positive clinical data for its obesity pipeline, including strong results for its next-generation injectable retatrutide and oral pill Foundayo, which reinforce the company's competitive dominance in the GLP-1 market. The community is actively discussing the stock's trajectory, potential for a stock split, and its role as a stable cornerstone asset in a broader portfolio rotation toward high-quality healthcare names.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is currently a focal point of intense community speculation, with retail investors attempting to force a short squeeze by piling into shares and encouraging long-term holding to counteract short-selling pressure. The trend is fueled by nostalgia for fast-food culture and a narrative that the company's dividend-paying fundamentals and potential for a corporate turnaround make it an undervalued, meme-worthy target similar to past retail-driven market events.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently drawing intense investor attention as its technology is increasingly viewed as a critical infrastructure solution to the AI power bottleneck, despite recent volatility driven by institutional rotation and project updates. The community remains deeply divided, with many bulls pointing to a robust hyperscaler backlog and long-term grid integration potential, while skeptics emphasize valuation concerns and the risks associated with scaling operations.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors weigh the potential impact of a long-awaited appellate court decision regarding Medicare bundling against the company's strong revenue growth and expanding commercial presence. The community is actively debating the stock's valuation disconnect and potential consolidation in the nephrology sector, with many long-term shareholders remaining focused on fundamental execution while monitoring institutional activity for signs of a turnaround.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is experiencing a period of intense volatility and market scrutiny as investors weigh its long-term AI-driven platform potential against the results of its Phase 1 clinical data. The community remains deeply divided, with some highlighting strong institutional accumulation and the upcoming Phase 2 catalyst for its lead molecule, while others express frustration over multi-year share price underperformance and the company's reliance on pipeline developments rather than immediate revenue growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan.read more...

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $137.00 at Royal Bank Of Canada

Royal Bank Of Canada increased their price objective on shares of Rhythm Pharmaceuticals from $136.00 to $137.00 and gave the company an "outperform" rating in a research report on Wednesday...

Wells Fargo & Company Boosts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $144.00

Wells Fargo & Company boosted their price target on Rhythm Pharmaceuticals from $143.00 to $144.00 and gave the stock an "overweight" rating in a research note on Wednesday...

Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday

Key PointsThe biotech was in the headlines recently after the FDA approved a new indication for its single commercialized drug...

Rhythm Pharmaceuticals Q1 Earnings Call Highlights

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported first-quarter 2026 revenue growth as the company began its U.S. commercial launch of IMCIVREE for acquired hypothalamic obesity (HO) and highlighted new regulatory progress in Europe and Japan.

First-quarter results show continued IMCIVREE growth

Chair...

Rhythm Pharmaceuticals (NASDAQ:RYTM) Announces Earnings Results

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.83) earnings per share for the quarter, topping analysts' consensus...

Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up  After Earnings Beat

Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up on Better-Than-Expected Earnings...

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +3.04% and +5.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Vanguard Group Inc. Purchases 1,214,489 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

Vanguard Group Inc. boosted its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 24.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,210,916 shares of the company's stock after buying an ad...

Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by Jennison Associates LLC

Jennison Associates LLC grew its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 123.2% in the 4th quarter, according to its most recent disclosure with the...

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Rhythm Pharmaceuticals Inc.

RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$107.22
Prev Close	$108.26
Open	$109.59
Dividend Yield	0.00%
50-Day Moving Average	$89.93
Beta	0.96
Avg. Volume	802,415.07
PE Ratio	-34.50

52-Week High	$122.20
52-Week Low	$61.00
Market Capitalization	$7.43B
EPS (Annual)	-$3.11
Price to Book	60.29
Revenue Per Employee	$458,350.24

Feed

News

Sentiment

Earnings

Fundamentals

Info

RYTMRhythm Pharmaceuticals Inc.

Latest RYTM News